Microgen Developed a New Russian Avian Influenza A (H7N9) Vaccine

04.09.2018
SPA Microgen of the Naсimbio holding (part of Rostec State Corporation), together with leading Russian research institutions in the field of influenza prevention, based on the Irkutsk branch, created a new Russian live vaccine against a potentially pandemic H7N9 avian influenza virus. The product will help combat the disease in case of a pandemic.

The development of an experimental series of a new live influenza vaccine against highly pathogenic influenza A/17/Hong Kong/2017/75108 (H7N9) was completed in August. The work on vaccine production was carried out with the support of the World Health Organization (WHO).

The Irkutsk branch of SPA Microgen has developed and manufactured an experimental series of a new product based on the vaccine influenza strain produced by the Institute of Experimental Medicine. Documents for conducting clinical trials of the new vaccine were transferred to the Ministry of Health of the Russian Federation in August.

Recall that in 2018, the avian influenza virus was detected in several regions of Russia, including Tatarstan and Chuvashia, Samara, Saratov, Penza, Nizhny Novgorod and a number of other areas.